Future prospect of "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients"

被引：0
|
作者：
Kang, Yong-Bo [1 ]
Cai, Yue [1 ]
机构：
[1] Shanxi Med Univ, Dept Microbiol & Immunol, Sch Basic Med Sci, Wenhua St, Jinzhong 030600, Shanxi, Peoples R China
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2022年 / 28卷 / 20期
关键词：
Gut microbiome; Immunotherapy; Immune checkpoint inhibitor resistance; Probiotics; Faecal microbiota transplantation; Hepatocellular carcinoma; Prognosis;
D O I：
10.3748/wjg.v28.i20.2248
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Recently, we read the article "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients" with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.
引用
收藏
页码：2248 / 2250
页数：3
相关论文
共 50 条
  • [41] Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
    Su, Yung-Yeh
    Lee, Wei-Hsiang
    Wang, Jing-Houng
    Wang, Hung-Wei
    Chen, Teng-Wei
    Chen, Bang-Bin
    Ho, Hsiu J.
    Liu, Tsung-Hao
    Chou, Shu-Cheng
    Chen, Bor-Rong
    Liu, Tsang-Wu
    Chen, Li-Tzong
    Wu, Chun-Ying
    Hsu, Chiun
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
  • [42] Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept
    Khene, Zine-Eddine
    Mathieu, Romain
    Peyronnet, Benoit
    Kokorian, Romain
    Gasmi, Anis
    Khene, Fares
    Rioux-Leclercq, Nathalie
    Kammerer-Jacquet, Solene-Florence
    Shariat, Shahrokh
    Laguerre, Brigitte
    Bensalah, Karim
    WORLD JOURNAL OF UROLOGY, 2021, 39 (09) : 3707 - 3709
  • [43] Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab
    Mohamed, Yehia I.
    Lee, Sunyoung S.
    Demir, Tarik
    Chamseddine, Shadi
    Hu, Zishuo Ian
    Xiao, Lianchun
    Elsayes, Khaled
    Morris, Jeffrey S.
    Wolff, Robert A.
    Hiatia, Rikita
    Qayyum, Aliya
    Rashid, Asif
    Duda, Dan G.
    Yao, James C.
    LaPelusa, Michael
    Koay, Eugene J.
    Mahvash, Armeen
    Al Azzam, Ahmed
    Dumbrava, Ecaterina E.
    Hassan, Manal
    Amin, Hesham M.
    Kaseb, Ahmed Omar
    CANCER BIOMARKERS, 2024, 41 (01) : 83 - 91
  • [44] Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08)
    Sunakawa, Y.
    Matoba, R.
    Inoue, E.
    Sakamoto, Y.
    Kawabata, R.
    Ishiguro, A.
    Akamaru, Y.
    Kito, Y.
    Takahashi, M.
    Matsuyama, J.
    Yabusaki, H.
    Makiyama, A.
    Suzuki, T.
    Tsuda, M.
    Yasui, H.
    Hihara, J.
    Takeno, A.
    Kawakami, H.
    Muro, K.
    Nakajima, T.
    Ichikawa, W.
    Fujii, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S223 - S224
  • [45] Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08)
    Sunakawa, Yu
    Matoba, Ryo
    Inoue, Eisuke
    Sakamoto, Yasuhiro
    Kawabata, Ryohei
    Ishiguro, Atsushi
    Akamaru, Yusuke
    Kito, Yosuke
    Takahashi, Masazumi
    Matsuyama, Jin
    Yabusaki, Hiroshi
    Makiyama, Akitaka
    Suzuki, Takahisa
    Tsuda, Masahiro
    Yasui, Hisateru
    Kawakami, Hisato
    Muro, Kei
    Nakajima, Takako Eguchi
    Ichikawa, Wataru
    Fujii, Masashi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [46] Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma
    Singal, Amit G.
    Zhang, Peng
    Waljee, Akbar K.
    Ananthakrishnan, Lakshmi
    Parikh, Neehar D.
    Sharma, Pratima
    Barman, Pranab
    Krishnamurthy, Venkataramu
    Wang, Lu
    Wang, Stewart C.
    Su, Grace L.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2016, 7
  • [47] Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
    Tien S. Dong
    Jonathan P. Jacobs
    Vatche Agopian
    Joseph R. Pisegna
    Walid Ayoub
    Francisco Durazo
    Pedram Enayati
    Vinay Sundaram
    Jihane N. Benhammou
    Mazen Noureddin
    Gina Choi
    Venu Lagishetty
    Oliver Fiehn
    Marc T. Goodman
    David Elashoff
    Shehnaz K. Hussain
    Digestive Diseases and Sciences, 2022, 67 : 3831 - 3841
  • [48] Duodenal Microbiome and Serum Metabolites Predict Hepatocellular Carcinoma in a Multicenter Cohort of Patients with Cirrhosis
    Dong, Tien S.
    Jacobs, Jonathan P.
    Agopian, Vatche
    Pisegna, Joseph R.
    Ayoub, Walid
    Durazo, Francisco
    Enayati, Pedram
    Sundaram, Vinay
    Benhammou, Jihane N.
    Noureddin, Mazen
    Choi, Gina
    Lagishetty, Venu
    Fiehn, Oliver
    Goodman, Marc T.
    Elashoff, David
    Hussain, Shehnaz K.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (08) : 3831 - 3841
  • [49] Can alfa-fetoprotein response to sorafenib predict for response and overall survival in hepatocellular carcinoma?
    Durrani, Humdum Pasha
    Murthy, Hemant S.
    Sanaka, Sirish
    Punja, Punam
    Naidu, Salini Sathya
    Atluri, Prashanti
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Alterations in the gut microbiome in patients with esophageal carcinoma in response to esophagectomy and neoadjuvant treatment
    Hasuda, Hirofumi
    Ikeda, Tetsuo
    Makizaki, Yutaka
    Yokota, Haruka
    Tanaka, Yoshiki
    Ohno, Hiroshi
    Shimokawa, Mototsugu
    Matsuoka, Hiroya
    Kimura, Yasue
    Oki, Eiji
    Yoshizumi, Tomoharu
    SURGERY TODAY, 2023, 53 (06) : 663 - 674
12345